Tapan Maniar
Chief Medical Officer Oblenio Bio
Tapan is a Physician-Executive with over 15 years of industry experience spanning early discovery through commercial launches. Tapan served as Global Development Lead for Blincyto, at Amgen, when it became the first bispecific antibody therapy approved by FDA in 2014 and EMA in 2015. He most recently served as CMO at Avencell inc, where he led a 25-member clinical team developing switchable Allogeneic CAR-T therapies for AML and played a key role in securing a $115M Series B financing. At Atara Biotherapeutics he helped advance the first commercially approved Allogeneic cell therapy platform and built the first cell therapy program in autoimmune disease, for MS. At Dragonfly he directed a phase 1 cytokine program that was successfully partnered with BMS.
Tapan earned his BA in English Literature from Northwestern University and his MD from the University of Pennsylvania School of Medicine where he also completed a fellowship in Hematology-Oncology.
Seminars
- Determining the optimal time to deploy B-cell depletion, focusing on using ‘immune reset’ therapies early in the course of the disease development
- Comparing the efficacy of standard peripheral B-cell depletion against next-generation therapies designed to achieve a complete, deep-depletion
- Defining new clinical endpoints and securing regulatory approval for a curative-intent treatment that aims to halt disease progression early across a broad, heterogeneous autoimmune patient population
- Understanding the mechanism of action for bi- and tri-specific antibodies enhancing cytotoxicity and phagocytosis through forced proximity for B-cell depletion
- Exploring how multi-specificity can overcome therapeutic resistance by targeting multiple antigens across the B-cell lineage
- Managing CRS risk for CD3 engagement in non-oncology populations in non-IgG-like multi-specific antibody constructs
